Name – 7th Congress of the European Academy of Neurology (June 19 – June 22, 2021)
Mode – Virtual
CXCL12 and Osteopontin were found to be biomarkers of multiple sclerosis progression as per the new research presented at 7th Congress of the European Academy of Neurology. Primary progressive multiple sclerosis involves degenerative and inflammatory processes which are fewer than the aggressive inflammatory infiltrates observed in relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis. The study evaluated 34 pro and anti-inflammatory cytokines and chemokines in the cerebrospinal fluid. 16 primary progressive multiple sclerosis and 80 relapsing-remitting multiple sclerosis patients underwent clinical evaluation inclusive of Expanded Disability Status Scale (EDSS) assessment. The also underwent a 3-T brain MRI for the detection of white matter along with cortical lesion number and volume. The global and regional cortical thickness were also assessed. The results for primary progressive multiple sclerosis were consistent with higher levels of CXCL12 and the monocyte–related osteopontin. On the other hand, IL-10 were significantly increased in relapsing-remitting multiple sclerosis patients. Other molecules and EDSS were not associated while increased gray matter lesion number and volume were observed in associated with CXCL12 levels. This analysis confirmed the role of chronic inflammation in primary progressive multiple sclerosis. This suggests that during diagnosis, presence of specific CSF protein profile can recognize early intrathecal inflammatory processes which can help distinguish primary progressive multiple sclerosis from relapsing-remitting multiple sclerosis improving the treatment of progressive multiple sclerosis.
